Table 1 Characteristics of patients with neuroblastoma in the training set and test set
Characteristics | All Patients (n = 133) | Training set (n = 93) | Test set (n = 40) | p value |
|---|---|---|---|---|
Age at diagnosis (years) | 3.2 (1.7–4.7) | 2.8 (1.4–4.7) | 3.4 (2.0–4.7) | 0.520 |
Gender | 0.866 | |||
Female | 75 (54.7%) | 52 (54.8%) | 23 (54.5%) | |
Male | 58 (45.3%) | 41 (45.2%) | 17 (45.5%) | |
BMI | 0.865 | |||
Yes | 65 (48.9%) | 45 (48.4%) | 20 (50.0%) | |
No | 68 (51.1%) | 48 (51.6%) | 20 (50.0%) | |
Maximum diameter(cm) | 9.5 ± 3.9 | 9.3 ± 3.6 | 10.0 ± 4.6 | 0.373 |
MYCN Status | 0.845 | |||
Amplified | 22 (17.3%) | 15 (16.7%) | 7 (18.2%) | |
Not Amplified | 111 (82.7%) | 78 (83.3%) | 33 (81.8%) | |
11q Aberration | 0.575 | |||
Yes | 55 (41.0%) | 37 (45.2%) | 18 (34.5%) | |
No | 78 (59.0%) | 56 (54.8%) | 22 (65.5%) | |
1p Aberration | 0.598 | |||
Yes | 52 (41.0%) | 35 (41.7%) | 17 (40.0%) | |
No | 81 (59.0%) | 58 (58.3%) | 23 (60.0%) | |
INSS Stage | 0.435 | |||
1, 2, 3, 4S | 43 (30.9%) | 32 (31.0%) | 11 (30.9%) | |
4 | 90 (69.1%) | 61 (69.0%) | 29 (69.1%) | |
COG Risk Stratification | 0.540 | |||
Low, Intermediate | 45 (32.4%) | 33 (31.0%) | 12 (34.5%) | |
High | 88 (67.6%) | 60 (69.0%) | 28 (65.5%) | |
NSE (ng/mL) | 237.5 (64.5–631.5) | 217.9 (61.7–532.3) | 315.3 (72.9–798.6) | 0.290 |
Ferritin (ng/mL) | 214.5 (72.8–295.8) | 232.4 (91.2–303.5) | 153.6 (64.6–288.6) | 0.421 |
LDH (U/L) | 578.0 (339.5–1038.0) | 567.0 (339.5–904.5) | 656.5 (342.0–1184.5) | 0.589 |
VMA (μmol/L) | 162.5 (46.2–501.8) | 162.5 (49.8–552.6) | 162.5 (32.2–473.3) | 0.937 |
HVA (μmol/L) | 36.4 (14.2–92.3) | 36.4 (13.8–91.4) | 36.4 (20.4–186.1) | 0.595 |
SUVmax | 5.4 (4.0–7.8) | 5.2 (4.0–8.6) | 5.8 (4.0–7.6) | 0.941 |
SUVmean | 2.0 (1.6–2.6) | 2.0 (1.6–2.6) | 2.2 (1.6–2.6) | 0.669 |
MTV (mL) | 130.3 (52.5–292.5) | 130.3 (52.4–266.5) | 131.8 (54.4–364.6) | 0.772 |
TLG | 269.5 (95.5–651.4) | 248.0 (96.7–524.1) | 296.8 (86.2–854.0) | 0.662 |